Prostate cancer with different ERG status may show different FOXP3-positive cell numbers

Kaczmarczyk-Sekuła, Karolina; Gałązka, Krystyna; Glajcar, Anna; Miłek, Katarzyna; Dyduch, Grzegorz; Szpor, Joanna; Gołąbek, Tomasz; Szopiński, Tomasz; Chłosta, Piotr; Rubinkiewicz, Mateusz; Tyrak, Katarzyna Ewa; Okoń, Krzysztof

doi:10.5114/pjp.2016.65861

Cited by 7 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At least for ERG, these data appear to be reproducible in that they are similar to results from two previously published studies in European or European-American cohorts, both of which demonstrated a similar association between ERG expression and CD3+ T-cell density ( 21 , 46 ), as well as a separate study reporting a similar association with FOXP3+ cell density ( 47 ). However, the mechanism of this association remains unclear.…”

Section: Discussionsupporting

confidence: 88%

Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer

Kaur

Guedes

et al. 2018

Modern Pathology

View full text Add to dashboard Cite

The inflammatory microenvironment plays an important role in the pathogenesis and progression of tumors and may be associated with somatic genomic alterations. We examined the association of tumor infiltrating T-cell density with clinical-pathologic variables, tumor molecular subtype and oncologic outcomes in surgically-treated primary prostate cancer occurring in patients of European-American or African-American ancestry. We evaluated 312 primary prostate tumors, enriched for patients with African-American ancestry and high grade disease. Tissue microarrays were immunostained for CD3, CD8 and FOXP3 and were previously immunostained for ERG and PTEN using genetically validated protocols. Image analysis for quantification of T-cell density in tissue microarray tumor spots was performed. Automated quantification of T-cell densities in tumor-containing regions of tissue microarray spots and standard histologic sections were correlated (r=0.73, p<0.00001) and there was good agreement between visual and automated T-cell density counts on tissue microarray spots (r=0.93, p<0.00001). There was a significant correlation between CD3+, CD8+ and FOXP3+ T-cell densities (p<0.00001), but these were not associated with most clinical or pathologic variables. Increased T-cell density was significantly associated with ERG positivity (median 309 vs 188 CD3+ T-cells/mm2; p=0.0004) and also with PTEN loss (median 317 vs 192 CD3+ T-cells/mm2; p=0.001) in the combined cohort of matched European-American and African-American ancestry patients. The same association or a similar trend was present in patients of both ancestries when analyzed separately. When the African-American patients from the matched race set were combined with a separate high grade set of African-American cases, there was a weak association of increased FOXP3+ T-cell densities with increased risk of metastasis in multivariable analysis. Though high T-cell density is associated with specific molecular subclasses of prostate cancer, we did not find an association of T-cell density with racial ancestry.

show abstract

Section: Discussionsupporting

confidence: 88%

Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer

Kaur

Guedes

et al. 2018

Modern Pathology

View full text Add to dashboard Cite

show abstract

“…Hence, Gr-MDSC show a higher production of reactive oxygen species (ROS) when compared to Mo-MDSC, which, on the other hand, comparing to Gr-MDSC display increased expression of inducible nitric oxide synthase (NOS2) and NO production [19]. MDSC could also induce T regulatory cells, which are often correlated with cancer progression [20].…”

Section: Introductionmentioning

confidence: 99%

The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy

Siemińska¹,

Rychlicka-Buniowska²,

Jaszczyński³

et al. 2020

pjp

View full text Add to dashboard Cite

Prostate cancer is one of the most frequent cancers in men. Although several treatment options exist, their clinical effectiveness is still not satisfactory. One the possible reason of such situation might be the presence of myeloid-derived suppressor cells (MDSC) and their pro-tumorigenic activity. MDSC possess immunosuppressive ability and in many studies were shown to support tumor development and progression. In this study we addressed the question whether commonly used therapies of prostate cancer affect the level of MDSC populations in the patients' blood. We compared the level of granulocytic (Gr-MDSC), monocytic (Mo-MDSC) and early stage MDSC (eMDSC) in the blood of patients at different clinical stage and different tumor grading scores, who underwent either surgery or hormonal therapy alone or were given a combined treatment, including e.g. radiotherapy. The obtained results showed that the level of Gr-MDSC was significantly lower in all treated patients comparing to untreated group. On the other hand, surgery or hormonal therapy alone did not affect the level of Mo-MDSC. These results were independent of the PSA level, the tumor grading and clinical stage of the patients. In conclusion, we suggest that Mo-MDSC should be considered as a potential therapy target in the course of prostate cancer treatment to enhance its anti-tumor effectiveness.

show abstract

“…We previously identified several differences between the microenvironment of ERG+ and ERG-PC. In our material, the ERG+ cancers had a significantly denser microvascular network [10] and higher concentrations of FOXP3+ regulatory lymphocytes [7], mast cells [8] and other inflammatory cells [9]. Some of the diffe rences between ERG+ and ERG-PC were observed by other authors as well [29,30].…”

Section: A B a Bmentioning

confidence: 59%

“…In our previous studies, we estimated the proportion of ERG+ cases in Poland at 46%; we also revealed several differences in tumor morphology and in particular the microenvironment [7][8][9][10]. Some studies have suggested that miRNAs may influence the biology of PC, including its invasiveness and response to antiandrogen treatment [11,12].…”

Section: Introductionmentioning

confidence: 99%

No differences in miRNA expression in the stroma of ERG+ and ERG– prostate cancers

Wątor,

Kołton-Wróż,

Wołkow

et al. 2023

pjp

View full text Add to dashboard Cite

Prostate cancer (PC) is one of the most common cancers in males. A significant proportion of PCs bear TMPRSS2-ETS translocation and overexpress ERG transcription factor, allowing classification into ERG+ and ERG-groups, which differ in several features including the tumor microenvironment. The aim of the study was to verify whether they differ in expression of the miRNA in the microenvironment. The material consisted of 150 radical prostatectomies. Immunohistochemistry (IHC) for ERG was done using a routine method. FISH for TMPRSS2-ETS translocation was done with a ZytoLight SPEC ERG/TMPRSS2 TriCheck Probe. From each case, a representative section was selected, and tumor and non-tumor were microdissected with the LMD7000 device. RNA was isolated using the RNeasy Mini Kit system (Qiagen) and miRNA libraries were prepared with the NEBNext Multiplex Small RNA Library Prep Set for Illumina and their sequencing was performed on the NexSeq 500. Statistical analysis was done with Statistica and R software. When analyzing the expression of miRNAs some differences could be seen, but after correction for multiple comparisons was applied, these were found to be nonsignificant.

show abstract

Prostate cancer with different ERG status may show different FOXP3-positive cell numbers

Cited by 7 publications

References 30 publications

Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer

Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer

The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy

No differences in miRNA expression in the stroma of ERG+ and ERG– prostate cancers

Contact Info

Product

Resources

About